About Q2Pharma

Q2Pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR)

Revolutionizing the Treatment of Bacterial Infections

Q2 Pharma is developing small-molecule antivirulence agents against bacterial infections.

Q2pharma was founded in 2015 by four experts in drug discovery and biotechnology committed to combating resistance to antibiotics. Based in Israel, Q2Pharma holds 2 patents through the United States Patent and Trademark Office issued in 2011 and 2014, as well as an exclusive licensing agreement with Case Western Reserve University from Cleveland, Ohio for our lead compound, F19. With experienced advisors from diverse backgrounds, the Q2Pharma team is working towards a long-term solution to one of the most pressing issues of our time.


  • Menachem Shoham PhD, Co-founder, Chief Scientific Officer
  • Jacob BenArie, MBA, Co-founder, Chief Executive Officer
  • Yaron Shoham, Co-founder, Chief Medical Officer
  • Yair Alegranti, Co-founder, Chief Translational Officer